MB-102 Dye for Retinal Disorders

Recruiting in Palo Alto (17 mi)

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase < 1

Waitlist Available

Sponsor: MediBeacon

No Placebo Group

Trial Summary

What is the purpose of this trial?The objective of this study is to evaluate the safety and image quality of the investigational dye, MB-102, compared to the control dye (fluorescein sodium) in healthy and diseased eyes using fluorescent angiography for retinal vascular disease diagnosis and monitoring.

Eligibility Criteria

This trial is for adults over 18 with retinal or choroidal vascular diseases who can follow the study rules. Women must not be pregnant and willing to use birth control, and men must agree to contraception post-dose. It's not for those with conditions affecting eye imaging, in other trials, or unstable health.

Inclusion Criteria

I agree to use birth control or abstain from sex for 7 days after my last dose.

I am older than 18 years.

Participants willing to comply with study requirements

+3 more

Exclusion Criteria

I have had seizures in the past.

You have had problems with drugs or alcohol in the past year.

You are unable to undergo eye exams.

+7 more

Participant Groups

The study compares a new dye called MB-102 against a standard dye, fluorescein sodium, in producing eye images using different cameras. The goal is to assess MB-102's safety and the quality of images it provides for diagnosing and monitoring retinal diseases.

1Treatment groups

Experimental Treatment

Group I: Adult participants with normal or diseased eyesExperimental Treatment4 Interventions

500 mg dose of intravenous fluorescein sodium followed by ocular angiography; after a minimum of 3 days, participants will receive a single intravenous dose of MB-102 at 4 μmol/kg followed by ocular angiography